The MYC gene belongs to a family of transcription factors that under normal conditions it controls cell cycle progression (1). However, in multiple types of cancer, MYC is considered a Proto-oncogene (1). MYC gene deregulation is identified in multiple malignancies such as Burkitt’s lymphoma, diffuse large B-cell lymphoma, and B-cell lymphoma (2). MYC gene amplifications, rearrangements, and/or point mutations are considered the underlying mechanisms that induce MYC gene deregulation (1). Specifically, a MYC gene rearrangement is considered a prognostic marker in several cancer subtypes. MYC gene rearrangements can be identified using conventional cytogenetic techniques such as fluorescence in situ hybridization (FISH).